Vasomune Therapeutics is a private biotechnology company developing the next generation of medications to harness the body’s ability to defend against illness by modifying cellular response to disease.
The company’s drug candidate AV-001 targets a signaling molecule in the vasculature responsible for regulating barrier defense and the host vascular response to injury. In response to injury or infection, the host vascular response can become unconstrained driving impairment of lung function, edema in critical organs, and fluid loss that leads to organ dysfunction and death. AV-001 activates Tie2, a tyrosine kinase receptor expressed on the cell surface of endothelial cells in the vasculature. Activated Tie2 is important for maintaining vascular homeostasis which promotes barrier defense against vascular leakage, and counteracts vascular inflammation.
Published studies of AV-001 or its predecessor analog Vasculotide, have demonstrated efficacy in multiple preclinical models, including reduction of vascular dysfunction in trauma and pathogen-induced disease models. Vascular dysfunction is a foundational mechanism for multiple additional disease states such as:
Vasomune is initially developing AV-001 for the treatment of patients with pathogen-induced Acute Respiratory Distress Syndrome (ARDS).
AV-001, a synthetic Angiopoietin 1 mimetic, activates the Tie2 receptor which is highly expressed on the surface of endothelial cells located within the vasculature.. AV-001 is designed to interact with the Tie2 receptor on a binding domain distinct from the natural ligands Angiopoietin 1 and Angiopoietin 2.
Activation of Tie2 broadly promotes barrier defense against vascular leak and counteracts vascular inflammation by decreasing the activity of multiple pro-inflammatory factors. AV-001 represents a novel multifactorial approach that acts at the cellular and tissue-level. This approach is in contrast to the traditional highly specific lock and key therapies aimed at killing the pathogen or individual targets within the inflammatory response pathway. There are no clinically available medications to treat vascular leak.
Vasomune Therapeutics doses first patient in Phase 2a clinical study to evaluate AV-001 in patients hospitalized with severe COVID-19 disease. January 18, 2022 08:00 AM
Vasomune Receives a US $6.4 Million PRMRP Grant from the US Department of Defense and up to $2.8 Million from NRC IRAP to Support the
Vasomune Announces Preliminary Positive Phase 1 Clinical Trial Results for Vascular Normalization Therapy AV-001 was Safe and Well-Tolerated in Healthy Volunteers Vasomune plans to initiate
Vasomune is very pleased to announce that the company has received a substantial investment on behalf of the Government of Canada through the National Research
First subjects have been dosed in Phase 1 study of AV-001, a novel first-in-class therapeutic Should the Phase 1 results show AV-001 is safe and
TORONTO, Ontario – (Business Wire) – November 12, 2020 – Vasomune Therapeutics, Inc., a clinical-stage biopharmaceutical company, announced today the U.S. Food and Drug Administration
Vasomune Therapeutics is a private biotechnology company developing the next generation of medications to harness the body’s ability to defend against illness by modifying cellular response to disease.